STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis reflected an increase in.
ATRAG formulations for lung disease europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),.
The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to conference
Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.